- Home
- WLGS vs MBIO Comparison
WLGS vs MBIO Comparison
Compare WLGS & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- MBIO
- Stock Information
- Founded
- WLGS 1981
- MBIO 2015
- Country
- WLGS Hong Kong
- MBIO United States
- Employees
- WLGS N/A
- MBIO N/A
- Industry
- WLGS Engineering & Construction
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- WLGS Consumer Discretionary
- MBIO Health Care
- Exchange
- WLGS Nasdaq
- MBIO Nasdaq
- Market Cap
- WLGS 4.4M
- MBIO 4.7M
- IPO Year
- WLGS 2023
- MBIO N/A
- Fundamental
- Price
- WLGS $0.05
- MBIO $1.02
- Analyst Decision
- WLGS
- MBIO
- Analyst Count
- WLGS 0
- MBIO 0
- Target Price
- WLGS N/A
- MBIO N/A
- AVG Volume (30 Days)
- WLGS 37.9M
- MBIO 87.6K
- Earning Date
- WLGS 08-14-2025
- MBIO 08-12-2025
- Dividend Yield
- WLGS N/A
- MBIO N/A
- EPS Growth
- WLGS N/A
- MBIO N/A
- EPS
- WLGS N/A
- MBIO N/A
- Revenue
- WLGS $3,951,649.00
- MBIO N/A
- Revenue This Year
- WLGS N/A
- MBIO N/A
- Revenue Next Year
- WLGS N/A
- MBIO N/A
- P/E Ratio
- WLGS N/A
- MBIO N/A
- Revenue Growth
- WLGS N/A
- MBIO N/A
- 52 Week Low
- WLGS $0.04
- MBIO $1.01
- 52 Week High
- WLGS $9.66
- MBIO $31.00
- Technical
- Relative Strength Index (RSI)
- WLGS 25.41
- MBIO 35.22
- Support Level
- WLGS $0.05
- MBIO $1.01
- Resistance Level
- WLGS $0.05
- MBIO $1.10
- Average True Range (ATR)
- WLGS 0.02
- MBIO 0.07
- MACD
- WLGS 0.01
- MBIO -0.02
- Stochastic Oscillator
- WLGS 3.27
- MBIO 3.45
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED. WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, water supply and sewage disposal systems, and site project management.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.